Literature DB >> 8363375

Evaluation of bacterial interference and beta-lactamase production in management of experimental infection with group A beta-hemolytic streptococci.

I Brook1, J D Gilmore.   

Abstract

The in vivo effects of penicillin and cefprozil therapy on the interaction between organisms commonly recovered from inflamed tonsils were studied by using a subcutaneous abscess model in mice. These organisms were group A beta-hemolytic streptococci (GABHS), Streptococcus salivarius (which is capable of interfering with GABHS), and Staphylococcus aureus. In mice infected with GABHS and S. salivarius alone or in combination, penicillin eliminated both organisms and cefprozil eliminated GABHS and S. aureus but not S. salivarius. Penicillin did not, however, reduce the number of GABHS or S. salivarius in the presence of S. aureus. The present study demonstrated the ability of beta-lactamase-producing S. aureus to protect GABHS from penicillin. However, no such protection was present following the administration of cefprozil. Furthermore, the preservation of S. salivarius that interferes with GABHS growth may provide protection from reinfection with GABHS. This study supports and provides an explanation for the increased efficacies of cephalosporins administered orally over that of penicillin when treating patients with acute GABHS pharyngitis or tonsillitis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8363375      PMCID: PMC187993          DOI: 10.1128/AAC.37.7.1452

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Evaluation of beta-lactamase activity and microbial interference in treatment failures of acute streptococcal tonsillitis.

Authors:  K Roos; E Grahn; S E Holm
Journal:  Scand J Infect Dis       Date:  1986

2.  Treatment of patients with a history of recurrent tonsillitis due to group A beta-hemolytic streptococci. A prospective randomized study comparing penicillin, erythromycin, and clindamycin.

Authors:  I Brook; R Hirokawa
Journal:  Clin Pediatr (Phila)       Date:  1985-06       Impact factor: 1.168

3.  Possible role of the anaerobe in tonsillitis.

Authors:  S Reilly; P Timmis; A G Beeden; A T Willis
Journal:  J Clin Pathol       Date:  1981-05       Impact factor: 3.411

4.  Betalactamase-producing microorganisms in recurrent tonsillitis.

Authors:  K Tunér; C E Nord
Journal:  Scand J Infect Dis Suppl       Date:  1983

5.  Bacterial interference in the throat flora during a streptococcal tonsillitis outbreak in an apartment house area.

Authors:  E Grahn; S E Holm
Journal:  Zentralbl Bakteriol Mikrobiol Hyg A       Date:  1983-11

6.  In vitro protection of group A beta-hemolytic streptococci from penicillin and cephalothin by Bacteroides fragilis.

Authors:  I Brook; P Yokum
Journal:  Chemotherapy       Date:  1983       Impact factor: 2.544

7.  Frequency of ampicillin-resistant Haemophilus parainfluenzae in children.

Authors:  D W Scheifele; S J Fussell
Journal:  J Infect Dis       Date:  1981-03       Impact factor: 5.226

8.  BMY-28100, a new oral cephalosporin: antimicrobial activity against nearly 7,000 recent clinical isolates, comparative potency with other oral agents, and activity against beta-lactamase producing isolates.

Authors:  R N Jones; A L Barry
Journal:  Diagn Microbiol Infect Dis       Date:  1988-01       Impact factor: 2.803

Review 9.  The role of beta-lactamase-producing bacteria in the persistence of streptococcal tonsillar infection.

Authors:  I Brook
Journal:  Rev Infect Dis       Date:  1984 Sep-Oct

10.  Quantitative measurement of beta lactamase in tonsils of children with recurrent tonsillitis.

Authors:  I Brook; P Yocum
Journal:  Acta Otolaryngol       Date:  1984 Nov-Dec       Impact factor: 1.494

View more
  9 in total

Review 1.  Antibacterial therapy for acute group a streptococcal pharyngotonsillitis: short-course versus traditional 10-day oral regimens.

Authors:  Itzhak Brook
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

2.  Efficacy of penicillin versus cefdinir in eradication of group A streptococci and tonsillar flora.

Authors:  Itzhak Brook; Perry A Foote
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 3.  Comparison of European and U.S. results for cephalosporin versus penicillin treatment of group A streptococcal tonsillopharyngitis.

Authors:  M Pichichero; J Casey
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-06       Impact factor: 3.267

4.  Penicillin failure in the treatment of streptococcal pharyngo-tonsillitis.

Authors:  Itzhak Brook
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

5.  Evaluation of potential factors contributing to microbiological treatment failure in Streptococcus pyogenes pharyngitis.

Authors:  S M Kuhn; J Preiksaitis; G J Tyrrel; T Jadavji; D Church; H D Davies
Journal:  Can J Infect Dis       Date:  2001-01

6.  Alloiococcus otitidis Forms Multispecies Biofilm with Haemophilus influenzae: Effects on Antibiotic Susceptibility and Growth in Adverse Conditions.

Authors:  Chun L Chan; Katharina Richter; Peter-John Wormald; Alkis J Psaltis; Sarah Vreugde
Journal:  Front Cell Infect Microbiol       Date:  2017-08-02       Impact factor: 5.293

Review 7.  Treatment Challenges of Group A Beta-hemolytic Streptococcal Pharyngo-Tonsillitis.

Authors:  Itzhak Brook
Journal:  Int Arch Otorhinolaryngol       Date:  2016-06-03

8.  Molecular Cloning and Docking of speB Gene Encoding Cysteine Protease With Antibiotic Interaction in Streptococcus pyogenes NBMKU12 From the Clinical Isolates.

Authors:  Natesan Balasubramanian; Govintharaj Varatharaju; Vellasamy Shanmugaiah; Karuppiah Balakrishnan; Mandayam A Thirunarayan
Journal:  Front Microbiol       Date:  2018-08-07       Impact factor: 5.640

9.  Beta-lactamase-producing nontypeable Haemophilus influenzae fails to protect Streptococcus pneumoniae from amoxicillin during experimental acute otitis media.

Authors:  Eva Westman; Susanne Lundin; Ann Hermansson; Asa Melhus
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.